Nima Farzan, chief executive officer of Kinnate Biopharma Inc., stated, “Following the announcement of the Company’s strategic reprioritization, we are focused on advancing our pan-RAF inhibitor exarafenib in combination with binimetinib and our c-MET inhibitor KIN-8741, and are focusing our discovery efforts around our CDK4 selective inhibitor program. We remain committed to pursuing therapies that can improve outcomes and make a positive impact on patients’ lives while also maximizing value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KNTE:
- Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- Dell upgraded, Starbucks downgraded: Wall Street’s top analyst calls
- Kinnate Biopharma downgraded to Neutral from Outperform at Wedbush
- Kinnate Biopharma downgraded to Neutral from Buy at H.C. Wainwright
- Kinnate Biopharma downgraded to Neutral on uncertainty at Piper Sandler